CDK9-IN-2

CAS No. 1269815-17-9

CDK9-IN-2( CDK9 inhibitor II )

Catalog No. M11131 CAS No. 1269815-17-9

CDK9-IN-2 is a potent and selective CDK9 inhibitor with IC50 of <8 nM, example 4 in patent WO2011026917A1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 76 Get Quote
5MG 140 Get Quote
10MG 223 Get Quote
25MG 429 Get Quote
50MG 628 Get Quote
100MG 888 Get Quote
500MG 1782 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CDK9-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    CDK9-IN-2 is a potent and selective CDK9 inhibitor with IC50 of <8 nM, example 4 in patent WO2011026917A1.
  • Description
    CDK9-IN-2 is a potent and selective CDK9 inhibitor with IC50 of <8 nM, example 4 in patent WO2011026917A1.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CDK9 inhibitor II
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1269815-17-9
  • Formula Weight
    363.8138
  • Molecular Formula
    C18H19ClFN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    COC1=C(C=C(C=C1)F)C2=CC(=NC=C2Cl)NC(=O)C3CCCNC3
  • Chemical Name
    3-Piperidinecarboxamide, N-[5-chloro-4-(5-fluoro-2-methoxyphenyl)-2-pyridinyl]-, (3R)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Keith B Pfister, et al. Heteroaryl compounds as kinase inhibitors. 2011, WO2011026917A1.
molnova catalog
related products
  • 1NM-PP1

    1NM-PP1(PP1 Analog II) is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors(IC50=28 uM vSrc; 4.2 nM v-Src-as1 I338G).

  • CID44216842

    CID44216842 is a potent Cdc42-selective guanine nucleotide binding lead inhibitor.?

  • NU-6102

    A potent CDK1 and CDK2 inhibitor with IC50 of 9.5 nM and 5.4 nM against CDK1/cyclinB and CDK2/cyclinA3 respectively.